Heterogeneous Needs Not Fulfilled by Approved Incretin Drugs Alone

Tu Diep, Skye Bioscience’s COO discusses prevailing attitudes towards obesity’s changing definition as the result of a personal lifestyle choice to acceptance as a disease which require new paradigms in treatment.